Xenetic Polyxen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(3)
PJSC Pharmsynthez is leveraging Xenetic s PolyXen® technology to improve the pharmacological properties of its Epolong product candidate pursuant to a royalty-bearing collaboration agreement
Russian registration filing of Epolong, a polysialylated form of recombinant human erythropoietin, follows previously reported positive Phase 3 data for the treatment of anemia in patients with chronic kidney disease
FRAMINGHAM, MA / ACCESSWIRE /
February 16, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ( Xenetic or the Company ), a biopharmaceutical company focused on advancing XCART, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today announced its partner, PJSC Pharmsynthez ( Pharmsynthez ), has reported in a press release that it has started the registration phase of Epolong (erythropoietin and polysialic acid conjugate) by filing a registration dossier to obtain approval of Epolong in Russia for the treatm ....

United States , Leningradskaya Oblast , Jenene Thomas , Xenetic Polyxen , Jeffrey Eisenberg , Xenetic Biosciences , Takeda Pharmaceuticals Co , Xenetic Biosciences Inc , Lipoxen Technologies , Lipoxen Technologies Limited , Chief Executive Officer , Takeda Pharmaceuticals , North American , Private Securities Litigation Reform Act , ஒன்றுபட்டது மாநிலங்களில் , ஜெஃப்ரி ஐசன்பெர்க் , டாகேடா மருந்துகள் இணை , தலைமை நிர்வாகி அதிகாரி , டாகேடா மருந்துகள் , வடக்கு அமெரிக்கன் , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் ,